Skip to main content
Industry News
Nirsevimab may lower pediatric RSV risk, hospitalization

Researchers studied 1,453 infants and found that the incidence of medically attended respiratory syncytial virus-associated lower respiratory tract infection was 70.1% lower in those who received nirsevimab prophylaxis, compared with the placebo group. The findings in The New England Journal of Medicine also showed that the incidence of hospitalization for RSV-associated lower respiratory tract infection was 78.4% lower in the nirsevimab group, compared with controls.

Full Story: